Amivantamab Versus Alternative Real-World Anti-Cancer Therapies in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in the US and Europe

Girard N, Wolf J, Kim TM, Leighl N, Knott CS, Li T, Cabrieto J, Diels J, Sermon J, Mahadevia P, Schioppa CA, Sabari J. Amivantamab Versus Alternative Real-World Anti-Cancer Therapies in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in the US and Europe. ELCC 2023; 2023, 29 Mar-1 Apr.